Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders

被引：8

作者：

Chatterjee, Gaurav ^{[1
]}

Gujral, Sumeet ^{[1
]}

Subramanian, Papagudi G. ^{[1
]}

Tembhare, Prashant R. ^{[1
]}

机构：

[1] Tata Mem Hosp, Hematopathol Lab, ACTREC, Room 17-18,CCE Bldg, Navi Mumbai 410210, Maharashtra, India

来源：

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION | 2017年 / 33卷 / 03期

关键词：

Flow cytometry; Plasma cell disorders; Multiple myeloma; MINIMAL RESIDUAL DISEASE; BONE-MARROW MICROENVIRONMENT; ACUTE LYMPHOBLASTIC-LEUKEMIA; SMOLDERING MULTIPLE-MYELOMA; LIGHT-CHAIN AMYLOIDOSIS; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; WALDENSTROMS MACROGLOBULINEMIA; DIFFERENTIAL-DIAGNOSIS; PROLIFERATIVE ACTIVITY;

D O I：

10.1007/s12288-017-0822-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multicolor flow cytometric (MFC) immunophenotyping is one of the basic test that is needed in the evaluation of hematolymphoid malignancies. Previously, there has been some reluctance in the use of MFC in plasma cell disorders (PCD). It was mainly due tolack of standardization, inadequate experience and detection of the lower number of plasma cells by MFC as compared to morphology. However, MFC has gone through many technological advancements in the last few years and a wide variety of reagents are now commercially available which worldwide allowed the establishment of standardized sensitive MFC-based immunophenotypic assay for PCD. Various studies have proven that MFC has a high clinical relevance in the diagnosis and risk stratification of multiple myeloma, its precursor conditions and other PCDs. Moreover, recent studies have shown that MFC is a highly sensitive and reliable technique for the monitoring of clinical response in the era of novel therapies. In this review, we have discussed the various applications of MFC in the management of PCD and their clinical relevance.

引用

页码：303 / 315

页数：13

共 93 条

[11] International Myeloma Working Group molecular classification of multiple myeloma: spotlight review [J].

Fonseca, R. ;

Bergsagel, P. L. ;

Drach, J. ;

Shaughnessy, J. ;

Gutierrez, N. ;

Stewart, A. K. ;

Morgan, G. ;

Van Ness, B. ;

Chesi, M. ;

Minvielle, S. ;

Neri, A. ;

Barlogie, B. ;

Kuehl, W. M. ;

Liebisch, P. ;

Davies, F. ;

Chen-Kiang, S. ;

Durie, B. G. M. ;

Carrasco, R. ;

Sezer, Orhan ;

Reiman, Tony ;

Pilarski, Linda ;

Avet-Loiseau, H. .

LEUKEMIA, 2009, 23 (12) :2210-2221

[12] Methodological Aspects of Minimal Residual Disease Assessment by Flow Cytometry in Acute Lymphoblastic Leukemia: A French Multicenter Study [J].

Fossat, Chantal ;

Roussel, Mikael ;

Arnoux, Isabelle ;

Asnafi, Vahid ;

Brouzes, Chantal ;

Garnache-Ottou, Francine ;

Jacob, Marie-Christine ;

Kuhlein, Emilienne ;

Macintyre-Davi, Elizabeth ;

Plesa, Adriana ;

Robillard, Nelly ;

Tkaczuk, Jean ;

Ifrah, Norbert ;

Dombret, Herve ;

Bene, Marie C. ;

Baruchel, Andre ;

Garand, Richard .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2015, 88 (01) :21-29

[13] Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients [J].

García-Sanz, R ;

González-Fraile, MI ;

Mateo, G ;

Hernández, JM ;

López-Berges, MC ;

de las Heras, N ;

Fernández-Calvo, J ;

Ortega, F ;

Portero, JA ;

Bárez, A ;

Galende, J ;

Orfäo, A ;

San Miguel, JF .

INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (05) :884-889

[14] Primary plasma cell leukemia:: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics [J].

García-Sanz, R ;

Orfao, A ;

González, M ;

Tabernero, MD ;

Bladé, J ;

Moro, MJ ;

Fernández-Calvo, J ;

Sanz, MA ;

Pérez-Simón, JA ;

Rasillo, A ;

San Miguel, JF .

BLOOD, 1999, 93 (03) :1032-1037

[15] Utility of immunophenotyping of plasma cells in multiple myeloma [J].

Gertz, Morie A. ;

Buadi, Francis K. .

LEUKEMIA & LYMPHOMA, 2016, 57 (02) :252-253

[16]

GIRINO M, 1991, ACTA HAEMATOL-BASEL, V85, P26

[17] Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma [J].

Gonsalves, W. I. ;

Rajkumar, S. V. ;

Gupta, V. ;

Morice, W. G. ;

Timm, M. M. ;

Singh, P. P. ;

Dispenzieri, A. ;

Buadi, F. K. ;

Lacy, M. Q. ;

Kapoor, P. ;

Gertz, M. A. ;

Kumar, S. K. .

LEUKEMIA, 2014, 28 (10) :2060-2065

[18] Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis [J].

Hill, Quentin A. ;

Rawstron, Andy C. ;

de Tute, Ruth M. ;

Owen, Roger G. .

BLOOD, 2014, 124 (08) :1296-1299

[19] Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting [J].

Irving, Julie ;

Jesson, Jenny ;

Virgo, Paul ;

Case, Marian ;

Minto, Lynne ;

Eyre, Lisa ;

Noel, Nigel ;

Johansson, Ulrika ;

Macey, Marion ;

Knotts, Linda ;

Helliwell, Margaret ;

Davies, Paul ;

Whitby, Liam ;

Barnett, David ;

Hancock, Jeremy ;

Goulden, Nick ;

Lawson, Sarah .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (06) :870-874

[20] Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia [J].

Karawajew, Leonid ;

Dworzak, Michael ;

Ratei, Richard ;

Rhein, Peter ;

Gaipa, Giuseppe ;

Buldini, Barbara ;

Basso, Giuseppe ;

Hrusak, Ondrej ;

Ludwig, Wolf-Dieter ;

Henze, Guenter ;

Seeger, Karl ;

von Stackelberg, Arend ;

Mejstrikova, Ester ;

Eckert, Cornelia .

HAEMATOLOGICA, 2015, 100 (07) :935-944

← 1 2 3 4 5 6 7 8 9 10 →